TABLE 6.

Experimental and clinical trials with drug targeting H3 methylation modulators in RCa.

Target	Drug	Combination	Tumor type	Status	Trial number	References
EZH2	Tazemetostat	-	RCC	Expanded access	NCT03874455	Epizyme Inc. (2019b)
	Tazemetostat	-	Renal Medullary Carcinoma Rhabdoid Tumors of the Kidney	Phase 2	NCT02601950	Epizyme Inc. (2015)
	Valemetostat (DS3201)	Ipilimumab	mCRCC	Recruiting	NCT04388852	M.D. Anderson Cancer Center (2020)
G9a	BIX-01294	TRAIL	Human RCa cell lines	Experimental	-	Woo et al. (2018)